Ironwood Pharmaceuticals initiated an internal organizational restructuring that includes cutting up to 100 full-time employees from payroll following a review of unblinded data from the company’s Phase III trials for IW-3718-302, which show that the drug failed to reduce the severity of heartburn in patients with refractory gastroesophageal reflux disease (GERD).
For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
Heartburn sufferers who do not feel better with standard treatment, but who have no detectable reflux, tend to have greater distress and worse quality of life, according to a new study.
Ironwood Pharmaceuticals touted its Phase IIb drug candidate IW-3718 in adult patients with uncontrolled gastroesophageal reflux disease (GERD), but investors seem wary as share prices were down more than 7 percent.